Clinical trials: Angiogenesis
Fetal Growth Retardation
Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler
Open randomized non-inferiority controlled trial to examine the use of angiogenic factors (instead of feto-placental Doppler) for fetal growth restriction at term to reduce the rate of labor inductions, without worsening…
- Trial name
- GRAFD (NCT04502823)
- Testing
- Management based on sFlt-1/PlGF values
- Where
- 20 sites in Spain
- Volunteers
- 1,088 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Cesarean Section
Number of Previous Cesarean Sections on the Results of Angiogenic Factors.
Hypertensive disorders of pregnancy (HPT) are an important cause of maternal-feto-neonatal morbidity and mortality, being one of the three leading causes of maternal death in our country and in developing countries.
- Trial name
- NCT06166303
- Testing
- sFlt-1/PGIF
- Where
- Panama
- Volunteers
- 540 people
- Sponsor
- Saint Thomas Hospital, Panama
Laparoscopy.
Comparison of Systemic Response After Laparoscopies Performed With Standard and Low-Pressure Pneumoperitoneum
The purpose of the study was the comparative assessment of the influence of low and standard pressure CO2 pneumoperitoneum on the systemic inflammatory and angiogenic responses during the postoperative period after laparoscopic…
- Trial name
- NCT00567125
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Medical University of Lublin
Advanced Solid Tumors
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion study of AMG 780 in up to 62 subjects with advanced solid tumors.
- Trial name
- NCT01137552
- Testing
- AMG 780
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Amgen
Advanced Solid Tumors
A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
The purpose of this study is to determine if CVX-241 (PF-05057459) is safe and tolerable when given as weekly infusions to adult patients with advanced solid tumors.
- Trial name
- NCT01004822
- Testing
- CVX-241
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Colorectal Cancer
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01079780
- Testing
- cetuximab, ramucirumab, irinotecan hydrochloride
- Where
- 255 sites in United States
- Volunteers
- 136 people
- Sponsor
- Eastern Cooperative Oncology Group
Gestational Trophoblastic Neoplasia, Choriocarcinoma
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
The purpose of the study is to determine the overall response rate of single agent TRC105 and the combination of TRC105 and bevacizumab in patients with refractory GTN (including choriocarcinoma, placental site trophoblastic…
- Conditions
- Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor
- Trial name
- NCT02664961
- Testing
- TRC105, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Kaposi Sarcoma
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Background: Kaposi Sarcoma (KS) is common in people with human immunodeficiency virus (HIV) but can also occur in people who do not have HIV.
- Trial name
- NCT04941274
- Testing
- Abemaciclib
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Preeclampsia
Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung and Vascular Development
Pregnant mothers who develop high blood pressure and other vascular problems (preeclampsia) deliver babies with increased neonatal health problems, which include lung disease and vascular complications, later in life.
- Trial name
- NCT02639676
- Testing
- Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections
- Where
- United States
- Volunteers
- 292 people
- Sponsor
- Indiana University
Non Small Cell Lung Cancer
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
The study will enroll patients with prior IO therapy (alone or in combination with chemotherapy or in combination with other IO agents) regardless of the PD-L1 level, into a non-randomized combination trial, with primary endpoint…
- Trial name
- NCT03527108
- Testing
- Nivolumab, Ramucirumab
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Fox Chase Cancer Center
Advanced Cancer
PTC299 for Treatment of Advanced Cancer
Formation of new blood vessels (angiogenesis) is important for tumor growth in advanced cancer. It is known that tumors make a protein called vascular endothelial growth factor (VEGF).
- Trial name
- NCT00704821
- Testing
- PTC299, Docetaxel
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- PTC Therapeutics
Sarcoma, Soft Tissue
Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma
This is a prospective, multicentric, randomized, open label Phase II trial investigating whether the oral angiogenesis inhibitor nintedanib, as compared to the intravenous cytotoxic compound ifosfamide, given for patients with…
- Trial name
- ANITA (NCT02808247)
- Testing
- Nintedanib, Ifosfamide
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 80 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Research purposes: the research design in the late more than 2 lines TNBC prospective, multicenter, cohort study, respectively to observe Trop2 - ADC joint PD - 1 single or combined anti-angiogenesis drugs (macromolecular single…
- Trial name
- NCT06878625
- Testing
- Sacituzumab Govitecan combined with Toripalimab, Sacituzumab govitecan combined with anti-angiogenesis
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pregnancy Disease, Preeclampsia
Dietary Salicylates and Preeclampsia
Preeclampsia (PE) is an important pregnancy complication and cause of maternal and perinatal mortality and morbidity. The underlying etiology and pathophysiology of preeclampsia is incompletely understood but it involves…
- Conditions
- Pregnancy Disease, Preeclampsia, Diet Habit
- Trial name
- PreSal (NCT06239363)
- Where
- Poland
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Poznan University of Life Sciences
Sarcopenia in Elderly, Muscle Atrophy
Effects of Cyclical Blood Flow Restriction Exercise on Muscle Hypertrophy and Capillaries in Older Adults
The purpose of this study was to learn if low-load resistance exercise combined with cyclical blood flow restriction (BFR) could improve small blood vessel structure and muscle size in older adults.
- Conditions
- Sarcopenia in Elderly, Muscle Atrophy, Aging
- Trial name
- NCT07689487
- Testing
- Blood Flow Restriction (BFR), Conventional Low-Load Resistance Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Akdeniz University
Inguinal Hernia
Neo-angiogenesis in Inguinal Henia Implant ProFlor
The investigation is aimed at specifically demonstrating the ingrowth of newly formed vascular elements within ProFlor, a 3D dynamic responsive implant for inguinal hernia repair
- Trial name
- NCT04541316
- Testing
- ProFlor inguinal hernia device
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Cagliari
Non-small Cell Lung Cancer
A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)
The primary purpose of this study is to examine the safety of volociximab in combination with a standard treatment of carboplatin and paclitaxel in subjects previously untreated with chemotherapy for advanced stage (IIIB/IV)…
- Trial name
- NCT00654758
- Testing
- M200 (Volociximab), Carboplatin, Paclitaxel
- Volunteers
- 33 people
- Sponsor
- AbbVie
Recurrent High-Grade Gliomas, Malignant Gliomas
Bevacizumab for Recurrent Malignant Glioma
Background: Bevacizumab is a genetically engineered antibody that blocks the growth of new blood vessels in tumors. Inhibiting the formation of these blood vessels may slow or stop disease progression by diminishing the supply of…
- Trial name
- NCT00271609
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer
This study will evaluate the efficacy, safety and effect on quality of life of weekly paclitaxel plus bevacizumab as first line treatment in elderly patients (≥ 70 years old) with metastatic breast cancer.
- Trial name
- NCT01120158
- Testing
- Bevacizumab, Paclitaxel
- Where
- 11 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
Pancreatic Cancer
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.
- Trial name
- NCT01707758
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Kansas